Human bitter taste is mediated by the hTAS2R family of G protein-coupled receptors [1] [2] [3] [4] . The discovery of the hTAS2Rs enables the potential to develop specific bitter receptor antagonists that could be beneficial as chemical probes to examine the role of bitter receptor function in gustatory and nongustatory tissues. In addition, they could have widespread utility in food and beverages fortified with vitamins, antioxidants, and other nutraceuticals, because many of these have unwanted bitter aftertastes. We employed a high-throughput screening approach to discover a novel bitter receptor antagonist (GIV3727) that inhibits activation of hTAS2R31 (formerly hTAS2R44) by saccharin and acesulfame K, two common artificial sweeteners. Pharmacological analyses revealed that GIV3727 likely acts as an orthosteric, insurmountable antagonist of hTAS2R31. Surprisingly, we also found that this compound could inhibit five additional hTAS2Rs, including the closely related receptor hTAS2R43. Molecular modeling and site-directed mutagenesis studies suggest that two residues in helix 7 are important for antagonist activity in hTAS2R31 and hTAS2R43. In human sensory trials, GIV3727 significantly reduced the bitterness associated with the two sulfonamide sweeteners, indicating that hTAS2R antagonists are active in vivo. Our results demonstrate that small molecule bitter receptor antagonists can effectively reduce the bitter taste qualities of foods, beverages, and pharmaceuticals.
Summary
Human bitter taste is mediated by the hTAS2R family of G protein-coupled receptors [1] [2] [3] [4] . The discovery of the hTAS2Rs enables the potential to develop specific bitter receptor antagonists that could be beneficial as chemical probes to examine the role of bitter receptor function in gustatory and nongustatory tissues. In addition, they could have widespread utility in food and beverages fortified with vitamins, antioxidants, and other nutraceuticals, because many of these have unwanted bitter aftertastes. We employed a high-throughput screening approach to discover a novel bitter receptor antagonist (GIV3727) that inhibits activation of hTAS2R31 (formerly hTAS2R44) by saccharin and acesulfame K, two common artificial sweeteners. Pharmacological analyses revealed that GIV3727 likely acts as an orthosteric, insurmountable antagonist of hTAS2R31. Surprisingly, we also found that this compound could inhibit five additional hTAS2Rs, including the closely related receptor hTAS2R43. Molecular modeling and site-directed mutagenesis studies suggest that two residues in helix 7 are important for antagonist activity in hTAS2R31 and hTAS2R43. In human sensory trials, GIV3727 significantly reduced the bitterness associated with the two sulfonamide sweeteners, indicating that hTAS2R antagonists are active in vivo. Our results demonstrate that small molecule bitter receptor antagonists can effectively reduce the bitter taste qualities of foods, beverages, and pharmaceuticals.
Results and Discussion

Identification and Characterization of a Small Molecule Bitter Receptor Antagonist
To identify putative antagonists of the human hTAS2R31 bitter receptor, we constructed a double stable cell line expressing hTAS2R31 along with the chimeric G protein G 16gust44 in HEK293 cells. This cell line was used for high-throughput biomolecular screening via calcium imaging. After thorough data analysis of the screening set (17,854 compounds total) and hit selection, we identified 139 candidate antagonists. One compound in particular, GIV3727 (4-(2,2,3-trimethylcyclopentyl)butanoic acid), was selected as a robust inhibitor of hTAS2R31 ( Figure 1A ). Potency assessments in hTAS2R31-expressing cells revealed that the half-maximal inhibitory concentration (IC 50 ) of GIV3727 for both agonists was 6.4 6 2.4 mM (n = 3) for acesulfame K and 7.9 6 6.1 mM (n = 3) for saccharin ( Figure 1B ). Inhibition of hTAS2R31 was reversible, because cells that were preexposed to GIV3727 responded fully to the agonist upon washout of the antagonist (see Figure S1A available online). Furthermore, we found that GIV3727 similarly inhibited hTAS2R43 (see Figure S1B ), which is 88% identical to hTAS2R31 and can also be activated by saccharin and acesulfame K [5] , suggesting that this compound would be of interest for further study as a putative bitter taste inhibitor. The structural identity and purity of the original sample of GIV3727 ( Figure 1C ) were confirmed by gas chromatography-mass spectrometry. GIV3727 was resynthesized, and hTAS2R31 inhibition by the new batch was confirmed before proceeding with further experiments.
Given the structural dissimilarity between the antagonist and known agonists ( Figure 1C ), we examined whether GIV3727 was acting as a competitive or noncompetitive receptor antagonist. Concentration curves of hTAS2R31 agonists were constructed in the presence of fixed concentrations of the inhibitor. Increasing concentrations of GIV3727 resulted in a rightward shift of the dose-response curves for all three cognate bitter agonists (Figure 2 ), suggesting that it might act at an orthosteric position and competitively inhibit receptor activation [6, 7] . However, agonist efficacy was also diminished by GIV3727, as evidenced by the lower maximal signal amplitudes (Figure 2A ), which is typically indicative of allosteric antagonism or insurmountable inhibition [6, 7] . We observed that the EC 50 increased 3-to 10-fold for all three agonists, whereas the signal amplitude decreased by 35%-70% upon inclusion of 25 mM GIV3727 (Figure 2 ), and we conclude that GIV3727 is likely an orthosteric, insurmountable bitter receptor antagonist [6, 7] .
GIV3727 Inhibits Multiple hTAS2Rs
Because GIV3727 inhibited both hTAS2R31 and hTAS2R43, we were interested to determine whether it can inhibit other bitter receptors. Therefore, we examined the effects of 25 mM GIV3727 via calcium imaging by using a panel of transfected hTAS2Rs with known bitter agonists (18 of the 25 hTAS2Rs). The receptors and the corresponding bitter agonists [8] tested are shown in Table 1 along with the effects of GIV3727 on receptor activation. When possible, we utilized an EC 90 concentration of bitter agonist, with the exception of four hTAS2Rs. The low potency and the limited number of available agonists for these four receptors (hTAS2R3, 5, 7, and 13) did not allow for an accurate EC 90 value to be determined prior to testing of GIV3727. Therefore, we used the maximal concentration of agonists that activated the receptor without eliciting an artifactual calcium transient. We found that GIV3727 could significantly inhibit a total of six bitter taste receptors (hTAS2R4, 7, 31, 40, 43, and 49) among those tested (Table 1 (A) Dose-response curves for acesulfame K, sodium saccharin, and aristolochic acid were prepared, and the effects of 6, 12, or 25 mM GIV3727 on agonist activation of hTAS2R31-expressing cells were assessed via calcium imaging in the FLIPR. Data are presented as the mean 6 SEM of at least three separate experiments performed in quadruplicate and fitted in GraphPad Prism via a 4-parameter logistic fit equation. (B) Average EC 50 values obtained for acesulfame K, saccharin, and aristolochic acid, in the absence or presence of GIV3727, which were derived from each experiment used to generate the data in (A). There was a significant effect (p < 0.0001) of antagonist concentration on each agonist, as assessed by two-way analysis of variance (ANOVA). Post hoc tests (Bonferroni) showed that all three concentrations of the antagonist significantly (p < 0.0001) reduced receptor activation across all concentrations of agonist.
and four receptors exhibited dose-dependent inhibition by GIV3727 with varying potencies ( Figure S2A ). hTAS2R7 was among the receptors inhibited by GIV3727, but it is not clear whether inhibition occurs at an equivalent EC 90 concentration of agonists because of the low potency of the bitter agonist. Inhibition was reversible in hTAS2R40 and hTAS2R43, similar to hTAS2R31 ( Figure S2B ). Finally, we did not observe inhibition of the remaining hTAS2Rs by the antagonist. Together, these studies suggest that GIV3727 acts selectively in a subset of hTAS2Rs.
Inhibition of several hTAS2Rs by GIV3727 was somewhat surprising given the low sequence homology in this receptor family. Overall homology among the hTAS2Rs is only 30%-70% [1] , and we initially expected that the antagonist might interact with only hTAS2R31 and hTAS2R43. However, our observation that GIV3727 modulates several receptors seems to parallel emerging trends for bitter receptor agonists. For example, aristolochic acid actually activates three different bitter receptors: hTAS2R14, hTAS2R31, and hTAS2R43 [5, 9] . Similarly, we found that chlorpheniramine activates eight different hTAS2Rs, whereas diphenidol appears to activate 15 hTAS2Rs [8] . This suggests that antagonists, like agonists, have the capacity to interact with several bitter receptors, which raises interesting questions regarding possible mechanisms. One possible interpretation is that the three-dimensional architecture is still maintained among the hTAS2Rs despite the low sequence homology and that GIV3727 is capable of binding to multiple receptors. An alternate explanation is that GIV3727 is disrupting G protein coupling, which could also explain inhibition of several relatively unrelated receptors. However, a majority of receptors were not inhibited by GIV3727 despite signaling through the same chimeric G protein ( Table 1 ), suggesting that inhibition of agonistevoked signaling is specific to the hTAS2R subset. It will be of interest to determine whether the promiscuous activity of GIV3727 is a property shared by other chemical classes of bitter receptor antagonists.
Molecular Determinants of Antagonist Binding
Because GIV3727 inhibited several hTAS2Rs, it was of interest to identify key residues for recognition of this compound in the targeted receptors, hTAS2R31 and hTAS2R43. Such information could be useful for improving potency and selectivity of this antagonist series. During previous studies in our laboratory examining agonist specificity of the hTAS2Rs, we identified residues important for activation of the bitter taste receptors hTAS2R31, 43, and 46 [10] . We focused on these receptors because they are closely related and possess highly distinct agonist activation patterns and because the relatively few amino acid sequence differences should account for the pronounced differences in bitter agonist selectivities. The most obvious amino acid differences between these receptors are in transmembrane helix 7, where hTAS2R46 contains an acidic Glu 265 and a hydrophobic Ala
268
, whereas hTAS2R31 and hTAS2R43 both contain basic residues instead (Lys 265 and Arg
). Point mutagenesis of the corresponding positions in all three receptors revealed that agonist activation and receptor selectivity are largely determined by these two residues [10] . During the course of the current study, we constructed homology models for hTAS2R31 and hTAS2R43 with the crystal structure reported for the b-adrenergic receptor [11, 12] to examine these receptors for residues that may interact with GIV3727. Chemical optimization to improve potency of this scaffold indicated that the -COOH moiety is essential for antagonist activity because replacement of this group with an ester or corresponding alcohol abolished activity ( Figure S3 ). Therefore, we focused on possible key interaction sites for this moiety in the homology models. Docking of GIV3727 in the putative binding pocket indicated that Lys 265 and Arg 268 were also likely interaction sites for the -COOH group of the antagonist ( Figure 3A) . In Ballesteros-Weinstein nomenclature [13] , these residues occupy positions 7.39 and 7.42, respectively, and have been previously shown to participate in ligand binding in other G protein-coupled receptors (GPCRs) [14] [15] [16] [17] [18] [19] . Taken together, we reasoned that interaction of GIV3727 may also depend on the same two residues that we previously found to be important for agonist selectivity and activation.
To address this question, we tested the existing mutants from our prior agonist specificity studies for sensitivity to GIV3727. Consistent with our hypothesis, GIV3727 was more active in receptors harboring basic residues (native hTAS2R43 or hTAS2R46
), whereas introduction of the hTAS2R46-specific residues (E265, A268) into hTAS2R43 abolished activity ( Figure 3B ). Our data indicate that these two residues in helix 7 are important for antagonist activity in hTAS2R31 and hTAS2R43 and are consistent with the molecular modeling predictions. This also suggests that GIV3727 is likely binding in proximity to bitter agonists, because these same two residues also affect agonist specificity [10] . For example, introduction of K265 and R268 into hTAS2R46 confers sensitivity to aristolochic acid, which activates hTAS2R43 but is inactive in the native hTAS2R46 ( Figure S4) . Conversely, the hTAS2R43 K265E/R268A mutant can be activated by the hTAS2R46 agonist strychnine, whereas the native hTAS2R43 is insensitive to this compound ( Figure S4 ). Thus, these residues appear to be important for both agonist and antagonist activity. The importance of helix 7 in agonist and antagonist binding has been observed for other GPCRs, including hTAS1R3, a component of the sweet and umami taste receptor heterodimers [15, 20] . Elucidation of other residues within hTAS2R31 and hTAS2R43 should further define the degree of overlap between the agonist and antagonist binding sites.
To determine the individual contributions of each residue, we generated mutants of hTAS2R46 in which Lys 265 or Arg 268 were introduced individually and examined them for sensitivity to GIV3727. We found that introduction of Lys 265 into hTAS2R46 was sufficient to confer sensitivity to the antagonist that was indistinguishable from the double mutant, whereas we did not observe inhibition in the A268R single mutant ( Figure 3C ). We also did not observe inhibition by GIV3727 in other hTAS2R46 mutants harboring nonbasic Figure S2 .
amino acid substitutions such as E265D, E265Q, or A268G ( Figure 3C ). Together, these results suggest that a basic residue at position 7.39 is a key contact point for GIV3727, at least within the mutated hTAS2R46 backbone. However, because the GIV3727 is active in other hTAS2Rs lacking these two basic residues, we do not rule out the existence of other residues in determining antagonist binding or specificity for other hTAS2Rs. Furthermore, presence of a lysine in this position is not sufficient to confer sensitivity to GIV3727 in other hTAS2Rs, because hTAS2R50 also has a lysine at this site but is insensitive to the antagonist. This implies that residues from other helices or extracellular loops are more likely to determine sensitivity to GIV3727 in receptors other than hTAS2R31 and hTAS2R43.
GIV3727 Decreases Bitter Taste Intensity in Humans
Acesulfame K and saccharin, to a lesser extent, are commonly used as sugar substitutes for low-calorie food products, and their acceptance could be significantly increased by blocking the undesirable bitter tastes associated with them [21] . Therefore, we wanted to determine whether GIV3727 could reduce the bitter taste of acesulfame K in vivo via structured human taste trials. We employed a two-alternative forced-choice paradigm (2-AFC) [22] coupled with anchored taste intensity ratings in order to quantify the reduction in bitterness. Subjects were presented with two aqueous solutions in random order: a 2 mM acesulfame K control solution and the same acesulfame K solution containing 30 ppm (150 mM) of GIV3727. Panelists were asked to identify the solution that had the strongest bitter aftertaste and were then instructed to rate the bitter taste intensity of the solutions with an anchored line scale. In a separate experiment with the same cohort, subjects identified the sweetest solution and then rated the sweet taste intensity. We found that nearly all of the panelists (95% of cohort) selected the GIV3727 solution as the least bitter, indicating that inclusion of GIV3727 led to a significant (p < 0.001) and perceivable decrease in the bitter taste associated with acesulfame K (Figure 4A ). Furthermore, taste intensity ratings of the solutions revealed that GIV3727 significantly (p < 0.001) decreased the bitterness associated with acesulfame K from moderate to merely recognizable ( Figure 4A ). In contrast to the effects on bitter perception, GIV3727 had no effect on the perceived sweetness of acesulfame K, because only 55% of the panelists selected the control solution as more sweet ( Figure 4B) . Similarly, the perceived sweet intensity ratings obtained for the two solutions were not significantly different ( Figure 4B ). The lack of an effect on sweet taste perception was further confirmed in 2-AFC studies with sucrose, in which the sample containing GIV3727 could not be discriminated from the 7% sucrose reference ( Figure 4C ), further confirming that GIV3727 specifically affects only bitter taste perception. Furthermore, we found that GIV3727 has no discernable taste or aroma of its own, because an aqueous solution containing 30 ppm GIV3727 could not be discriminated from a water reference in a triangle test (n = 50, p = 0.196) [22] . Finally, similar results were also obtained in 2-AFC studies, with 3 mM saccharin as the taste stimulus, in which the reference was also identified as more bitter than the saccharin solution containing GIV3727 ( Figure 4D ). Together, our findings indicate that GIV3727 effectively reduces only the bitter taste associated with these two sweeteners.
It is notable that although GIV3727 abolished hTAS2R31 and hTAS2R43 receptor activation in vitro (Figure 1) , not all panelists detected a complete reduction in bitterness in vivo ( Figure 4A ). The taste intensity ratings revealed that GIV3727 reduced the bitterness of acesulfame K from moderate to recognizable, so it did not fully abolish the bitterness. Several factors may contribute to this apparent discrepancy between in vitro and in vivo results. In cell-based assays, receptor access is relatively unimpeded because the cells are bathed in the solution containing the antagonist. In contrast, anatomical constraints in vivo may limit compound access, leading to reduced efficacy. Single-nucleotide polymorphisms (SNPs) that affect bitter agonist activity in vitro and in vivo have been identified in the hTAS2R gene family [23] [24] [25] . It is possible that nonsynonymous SNPs or even genomic deletions within the hTAS2R31 and hTAS2R43 genes could diminish the effects of GIV3727 in a small number of individuals. Finally, the artificial sweeteners used in the current study elicit both sweet and bitter sensations, which may hinder discrimination between different taste solutions or taste attributes [26] . Nevertheless, our studies revealed that GIV3727 has efficacy in vivo in reducing the bitterness associated with the sulfonamide sweeteners, consistent with our in vitro findings.
Conclusions
In this paper, we describe the identification and characterization of GIV3727, which to our knowledge is the first reported small molecule bitter taste receptor antagonist with in vivo efficacy. Although lactisole or 2-(4-methoxyphenoxy)-propanoic acid is widely known as an inhibitor of the human sweet taste receptor [15, 27, 28] , this is the first antagonist targeting the hTAS2R bitter receptors. These results are an important step toward understanding how bitter taste perception and/or signaling can be modulated via small molecules. Furthermore, hTAS2R inhibitors could help to determine the contributions of bitter taste perception during the ingestion of a complex meal. Moreover, recent evidence indicates that bitter receptors are also expressed in other nongustatory tissues with proposed roles in the detection of noxious airborne chemicals [29] or regulation of glucose homeostasis via the gastrointestinal tract [30] . Bitter receptor antagonists such as GIV3727 could potentially be very useful as chemical probes to examine the precise contributions of bitter receptor signaling in nongustatory systems. Finally, this approach also has the potential to (A and B) The effects of GIV3727 on the bitterness (A) or sweetness (B) of 2 mM acesulfame K were determined by a two-alternative forced-choice paradigm (2-AFC) paired with anchored intensity ratings. Panelists were presented with sweetener alone or plus 30 ppm GIV3727 in random order and were asked to select the solution that was most bitter (A) or most sweet (B). The data on the left of each graph are the fraction of panelists (out of 22 total) that chose a given solution as the most bitter or sweet. We found that nearly all of the panelists (95% of cohort) selected the GIV3727 solution as less bitter, but they were unable to detect any effect on sweetness (55% [control] versus 45% [+GIV3727]). The data on the right of each graph show the effects of 30 ppm GIV3727 on the perceived bitter and sweet taste intensities, which were generated with a 0-100 line scale with anchors at the following points: 0 = no bitterness, 25 = recognizable, 50 = moderate, 75 = strong, 100 = extreme. The taste intensity data are plotted as the mean 6 SEM, and ANOVA was used to assess differences (samples and judges as main effects). We found that sample intensity ratings for bitterness were significantly different (F1,21 = 83.0; p < 0.001), but there was no effect on perceived sweet taste intensity of the GIV3727 solution (F1,21 = 0.10; p = 0.754). (C) Lack of an effect of GIV3727 on sweet taste of sucrose, as assessed via the 2-AFC method. Thirty panelists were presented with 7% sucrose alone or plus 36 ppm GIV3727 in random order and were asked to select the solution that was most sweet. Data are presented as the fraction of panelists that chose a given solution as the most sweet. Inclusion of GIV3727 had no significant effect on sweet taste perception of the sucrose solution (p = 0.856). (D) Effects of GIV3727 on bitterness of saccharin, as determined by 2-AFC. Statistical significance is indicated above the bar and was determined by a beta-binomial analysis.
improve the taste profile of packaged foods and beverages and to improve oral administration of bitter-tasting medicines.
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